Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Neuraxis, Inc. develops neuromodulation medical devices targeting pediatric and adult gastrointestinal and neurological conditions. Its core products include FDA-cleared non-invasive nerve stimulation systems for functional abdominal pain, IBS, and related disorders. The company leverages proprietary patents, clinical research, and strategic licensing to provide evidence-based, non-drug therapies that improve patient outcomes, primarily serving hospitals, clinics, and healthcare providers in the US and globally.
This description was generated via AI from an annual report. Updated about 1 year ago.